BID Knockout cell line (ACHN)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

BID (BH3 interacting domain death agonist) encodes a pro-apoptotic member of the BCL-2 protein family that links death receptor signaling to mitochondrial apoptosis. Following cleavage by caspase-8, the resulting C-terminal fragment translocates to mitochondria and promotes cytochrome c release, contributing to activation of the intrinsic apoptotic pathway.

Initiated in November 1979, ACHN is a well-established human cell line derived from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma. The cells were originally seeded directly into culture flasks in Eagle’s MEM supplemented with 10% FBS, and maintained through passages for 150 days before being inoculated subcutaneously into nude mice, where they formed palpable, locally invasive tumors within four weeks. Notably, both the parental ACHN cells and those recovered from the nude mouse tumors are distinctly growth-inhibited by human interferons, making ACHN a premier in vitro and in vivo model platform for investigating renal oncology progression, cytokine responses, and preclinical drug evaluation.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.